Department Chemie und Pharmazie


close-button

Project Types

Third Party Funds Group - Overall project
Third Party Funds Group - Sub project
Third party funded individual grant
Internally funded project
FAU own research funding: EFI / IZKF / EAM ...
Non-FAU Project

Status

Project year

From
To
Advanced SCILLs in electrosynthesis: Understanding and tailoring selective hydrogenation an dehydrogenation at ionic liquid interfaces (C05) (SFB 1452 CLINT C05) Catalysis at Liquid Interfaces (CLINT) (SFB 1452 CLINT) Jan. 1, 2021 - Dec. 31, 2024 Molecular interactions and reaction mechanisms in Advanced SCILLs: From ideal model experiments to real materials and operando studies (C03) (SFB 1452 CLINT C03) Catalysis at Liquid Interfaces (CLINT) (SFB 1452 CLINT) Jan. 1, 2021 - Dec. 31, 2024 Surface and interface science studies of Advanced SCILL systems (C02) (SFB 1452 CLINT C02) Catalysis at Liquid Interfaces (CLINT) (SFB 1452 CLINT) Jan. 1, 2021 - Dec. 31, 2024 Properties of the gas/liquid interface of Interface-enhanced SILP systems (B04) (SFB 1452 CLINT B04) Catalysis at Liquid Interfaces (CLINT) (SFB 1452 CLINT) Jan. 1, 2021 - Dec. 31, 2024 Task-specific ionic liquids and their Group 10 metal coordination complexes for Interface-enhanced catalysis (B01) (SFB 1452 CLINT B01) Catalysis at Liquid Interfaces (CLINT) (SFB 1452 CLINT) Jan. 1, 2021 - Dec. 31, 2024 Enhancing poisoning resistance and catalyst stability in dehydrogenation reactions through SCALMS (A06) (SFB 1452 CLINT A06) Catalysis at Liquid Interfaces (CLINT) (SFB 1452 CLINT) Jan. 1, 2021 - Dec. 31, 2024 Tuneable supports and geometry effects in SCALMS catalysis (A04) (SFB 1452 CLINT A04) Catalysis at Liquid Interfaces (CLINT) (SFB 1452 CLINT) Jan. 1, 2021 - Dec. 31, 2024 Characterising the active site in liquid metal catalysts (A01) (SFB 1452 CLINT A01) Catalysis at Liquid Interfaces (CLINT) (SFB 1452 CLINT) Jan. 1, 2021 - Dec. 31, 2024 Properties of the gas/liquid interface of Interface-enhanced SILP systems Katalyse an flüssigen Grenzflächen (CLINT) Jan. 1, 2021 - Dec. 31, 2024 Development and investigation of isotope-labelled antagonists for the orexin 1 receptor (OX1R) with subtype selectivity over OX2R July 1, 2020 - Nov. 30, 2024